Catalyst Pharmaceuticals, Inc.
CPRX
Hisse Senetlerindeki Sıralama
#4165
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Hisse Fiyatı
$31.49
Son senkronizasyon: 2026-07-21
Piyasa Değeri
$3.85B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
53.24%
Ülke
US
Ticaret Catalyst Pharmaceuticals, Inc. (CPRX)
Kategori
Healthcare
Catalyst Pharmaceuticals, Inc. (CPRX) için EPS
March 2026 itibariyle EPS TTM: $1.80
Catalyst Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $1.80'dir. 2023 yılı sonunda, şirketin EPS'si $0.67 idi; bu, 2022 yılındaki EPS olan $0.80 ile önceki yıla göre azalma.
Catalyst Pharmaceuticals, Inc. için 2002 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $1.80 | 30.43% |
| 2024 | $1.38 | 105.97% |
| 2023 | $0.67 | -16.25% |
| 2022 | $0.80 | 110.53% |
| 2021 | $0.38 | -47.22% |
| 2020 | $0.72 | 132.26% |
| 2019 | $0.31 | -193.94% |
| 2018 | $-0.33 | 57.14% |
| 2017 | $-0.21 | -4.55% |
| 2016 | $-0.22 | -12.00% |
| 2015 | $-0.25 | 4.17% |
| 2014 | $-0.24 | -11.11% |
| 2013 | $-0.27 | 92.86% |
| 2012 | $-0.14 | -51.72% |
| 2011 | $-0.29 | 31.82% |
| 2010 | $-0.22 | -54.17% |
| 2009 | $-0.48 | -40.74% |
| 2008 | $-0.81 | 145.45% |
| 2007 | $-0.33 | -8.33% |
| 2006 | $-0.36 | 24.14% |
| 2005 | $-0.29 | 61.11% |
| 2004 | $-0.18 | 20.00% |
| 2003 | $-0.15 | 36.36% |
| 2002 | $-0.11 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | 862.22% |
US
|
|
| $-7.98 | -543.33% |
US
|
|
| $-5.29 | -393.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,441.11% |
NL
|
